the aid library

Access to controlled medicines for pain management in the WHO South-East Asia Region

World Health Organisation (WHO) (2023) C_WHO

The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to thes ... more

Video: Nipple Pain

Global Health Media (2015)

Nipple pain in a breastfeeding mother is common but not normal. It often happens when women first start breastfeeding and is usually due to the baby not attaching deeply. This video shows how to evaluate and help mothers with nipple ... more

Images showing individual symptoms of Ebola: Stomach Pain

Centers for Disease Control and Prevention CDC (2014)

Guidelines on the management of chronic pain in children

World Health Organization WHO (2020) C_WHO

Guidelines on the management of chronic pain in children, developing and implementing national and local policies for pain management and protocols in children, implementing national and local regu ... more

WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings

World Health Organization WHO (2023) CC

The purpose of the guideline is to provide evidence-based recommendations on nonsurgical interventions for chronic primary LBP (CPLBP) in adults, including older people, that can be delivered in primary and community care settings to improve CPLBP-related health and well-being outcomes. For this rea ... more

WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings

World Health Organization WHO (2023) CC

Opioid overdose

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The World Health Organization's fact sheet on opioid overdose highlights the significant global health issue posed by opioids, which include natural, semi-synthetic, and synthetic compounds used primarily for pain management. Misuse and unsupervised ... more

Oxycodone

UCLA Brain Research Institute (2021) CC

The pamphlet "Oxycodone" provides an overview of the opioid drug class, explaining its uses, effects, and risks. It describes positive effects like euphoria and pain relief, alongside negative effects such as respiratory depression, confusion, and c ... more

Safe Anaesthesia

Lucille Bartholomeusz; Updated by J.Lees (2006) C1

This an updated revised edition of the book which is published in 1986 ,The whole text has been updated and revised in line with current anaesthetic teaching. New chapters on hypothermia and acute pain relief added and some other chapters for easier ... more

Long COVID symptoms

British Lung Fundation (2021) CC

This infographic shows the most common signs and symptoms of Long COVID. Breathlessness. Cough, sore throat. Chest pain. Pins and needles. Tinnitus, earaches.

Poster: Warning Signs of Severity of Dengue

World Health Organization World Health Organization WHO (2023) C_WHO

Poster on the warning signs of dengue severity. Many people with dengue can be cared for at home with adequate rest and hydration. But go immediately to the nearest medical center if you live in a dengue-prone area, and a few days after getting sick with fever, you experience: a drop in body tempera ... more

Abdominal tuberculosis in Ecuador, a problem that is still not solved

Rojas, C. L., Polanco E. C., Vivar M. C. et al. (2020) CC

Journal of Clinical TB and other Mycobacterial Diseases uberculosis (TB) in the gastrointestinal tract or peritoneum is an uncommon condition in clinical practice. Its rarity, combined with its nonspecific presentations, makes this kind of extrapulmonary tuberculosis difficult to diagnose as it can ... more

The Expanded Special Project for Elimination of Neglected Tropical diseases — ESPEN

World Health Organization World Health Organization WHO (2023) C_WHO

While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chronic ... more

Children’s Palliative Care and Human Rights

Open Society Foundation (2015) C1

Palliative care for children with life-limiting illness is the active total care of the child’s body, mind, and spirit. It begins at diagnosis and continues regardless of whether the child receives treatment directed at the disease. It seeks to control all forms of suffering related to the illness ... more

Progress Toward Global Eradication of Dracunculiasis

Hopkins, D.; Weiss, A.; Roy, S. Morbidity and Mortality Weekly Report MMWR; National Libary of Medicine (2020) CC

Dracunculiasis (Guinea worm disease), caused by the parasite Dracunculus medinensis, is traditionally acquired by drinking water containing copepods (water fleas) infected with D. medinensis larvae, but in recent years also appears increasingly to be transmitted by eating fish or other aquatic anima ... more

Mpox Outbreak Toolbox, Updated: January 2023

World Health Organization WHO; Health Cluster (2024) CC

i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back ... more

Global atlas of palliative care at the end of life

World Palliative Care Alliance; WHO (2020) C_WHO

The second edition of the WHPCA Global Atlas of Palliative Care was launched during World Hospice & Palliative Care Day 10 October. The Atlas is an update of the original WHPCA/WHO Global Atlas of Palliative care at the end of life published in 2014. It is full of useful facts and figures to support ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

COLERA: INFORMAÇA O PARA PROMOTORES DE SAUDE ou ACTIVISTAS

World Health Organisation (WHO) (2019) C2

The PDF "COLERA: Informação para Promotores de Saúde" provides essential guidance for health promoters and activists on cholera. It explains that cholera is characterized by severe watery diarrhea, often resembling rice water, and sometimes vomiting. If not treated promptly, it can lead to death ... more